Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab

Intern Med. 2019;58(10):1479-1484. doi: 10.2169/internalmedicine.1673-18. Epub 2019 May 15.

Abstract

Lynch syndrome is caused by mutations in mismatch repair genes that lead to microsatellite instability (MSI). An increased number of mutation-associated neoantigens have been observed in patients with high-frequency MSI (MSI-H) cancer; in addition, membranous programmed death ligand-1 (PD-L1) tends to be expressed at higher levels in MSI-H cancers than in microsatellite-stable cancers. MSI-H cancer patients are therefore considered to be susceptible to immune checkpoint blockade. We herein report for the first time a case of lung adenocarcinoma with Lynch syndrome and the response to nivolumab.

Keywords: Lynch syndrome; MSI-H; nivolumab.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Aged
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Colorectal Neoplasms, Hereditary Nonpolyposis / complications*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Male
  • Nivolumab / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab